Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Decreases By 10.5%

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a large decline in short interest during the month of June. As of June 30th, there was short interest totalling 227,800 shares, a decline of 10.5% from the June 15th total of 254,500 shares. Based on an average daily volume of 518,500 shares, the days-to-cover ratio is currently 0.4 days.

Astellas Pharma Trading Up 1.3 %

Shares of ALPMY opened at $10.46 on Monday. Astellas Pharma has a 52-week low of $9.15 and a 52-week high of $15.90. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.31. The firm’s fifty day moving average is $9.84 and its two-hundred day moving average is $10.53. The stock has a market cap of $18.93 billion, a PE ratio of 149.43 and a beta of 0.38.

Astellas Pharma (OTCMKTS:ALPMY) last announced its earnings results on Thursday, April 25th. The company reported $0.11 earnings per share (EPS) for the quarter. Astellas Pharma had a net margin of 1.20% and a return on equity of 5.85%. The company had revenue of $2.79 billion for the quarter. Research analysts forecast that Astellas Pharma will post 0.36 earnings per share for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.